
“More real than reality itself.” This is the sales pitch made by fans of dimethyltryptamine. Otherwise known as DMT, the compound found in ayahuasca returned to the spotlight recently thanks to Prince Harry’s description of his trips, which, he says, “cleared the windshield” of trauma from his mother’s death. Indeed, psychedelic drugs have shown some promise in treating disorders ranging from depression to PTSD; their proponents have suggested that the apparently mystical experiences they inspire could play a role in everything from preventing war to enabling a future of “net zero trauma”. These “psychotechnologies” often seem to work by providing, in the words of Walter Benjamin, a kind of “profane illumination”: a taste of something real.
Psychedelic trips have played a part in mystical traditions for millennia, but their revival comes at a time when our old religions are endangered. The march of Reason and Evidence has left a gaping void; we are surrounded by a bubbling sea of Unreality. Television, billboards and newspapers first threatened the dam between dreams and waking consciousness; Twitter, Netflix and the smartphone, always there and nudging away, have blasted it asunder.
In place of structural changes, or indeed religious ones, the system defaults to plaster solutions, offering mere jolts of aliveness. The “altered states economy”, now generating as much as $4 trillion worldwide, offers a range of techniques to tap into the Real, or at least muffle the Unreal. There’s alcohol and disposable vape pens, video gaming and high-intensity sports, breathwork, meditation apps — and now, the legal psychedelic drug, perhaps the most significant launchpad to sacred states yet.
Medical authorities in Oregon are set to roll out psychedelic therapy this year, while many cities and states in the US have, to various extents, decriminalised the drugs. Meanwhile, Mexico is tapping into the market for psychedelic experiences still illegal in the US: the Guardian reported yesterday on clinics set up just over the border that offer courses of the powerful psychedelic ibogaine as treatment for trauma.
The faith we once put in transcendent states has been swiftly industrialised. A scan of the current psychedelic market reveals a strange mix of Big Pharma and young start-ups, such as ATAI, a Peter Thiel-funded firm. Its founder, Christian Angermayer, has been accused of manoeuvring to dominate the psychedelic market through zealous patenting strategies. He envisions his trials as perpetuations of mystical traditions from Ancient Greece. More than 2,000 years later, though, “profane illumination” is now under the microscope, dissected, refashioned as a tool. Only when validated in scientific, psychiatric discourse is it taken seriously. The industrial boom has happened in tandem with an enormous amount of research, much of it funded (with likely biasing effects) by profit-driven entities.
Whereas psychedelic culture used to be defined by its naive subjectivism — you have to take it to know what it’s like, man! — a kind of naive objectivism has taken its place. On a scale of one-to-five, the Mystical Experience Questionnaire asks trial participants, how would you “sense that [your psychedelic] experience cannot be described adequately in words”?
Our grasping search for the Real is heading for more disturbing developments still. As documented by the scholars Maxim Tvorun-Dunn and Tehseen Noorani, efforts are underway to render “psychedelic medicine” continuous with growing suites of “digital therapeutics”. Some firms plan to substitute post-trip in-person therapy for an app. Other companies intend to track and harvest data from clients’ voyages, via wearable devices that “personalise” and “facilitate” the “clinical experience”.
Join the discussion
Join like minded readers that support our journalism by becoming a paid subscriber
To join the discussion in the comments, become a paid subscriber.
Join like minded readers that support our journalism, read unlimited articles and enjoy other subscriber-only benefits.
Subscribe